PMID- 37203212
OWN - NLM
STAT- MEDLINE
DCOM- 20231030
LR  - 20231030
IS  - 1525-1594 (Electronic)
IS  - 0160-564X (Linking)
VI  - 47
IP  - 10
DP  - 2023 Oct
TI  - Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual 
      antiplatelet therapy in patients supported with venoarterial extracorporeal 
      membrane oxygenation.
PG  - 1672-1677
LID - 10.1111/aor.14590 [doi]
AB  - BACKGROUND: Patients with refractory cardiogenic shock from an acute myocardial 
      infarction may receive percutaneous coronary intervention (PCI) and require the 
      use of venoarterial extracorporeal membrane oxygenation (VA-ECMO). The purpose of 
      this study was to compare bleeding and thrombotic events in patients treated with 
      cangrelor plus aspirin versus oral dual antiplatelet therapy (DAPT) while 
      supported with VA-ECMO. METHODS: We conducted a retrospective review of patients 
      who received PCI, were supported with VA-ECMO, and were treated with either 
      cangrelor plus aspirin or oral DAPT from February 2016 through May 2021 at 
      Allegheny General Hospital. The primary objective was the incidence of major 
      bleeding, defined as Bleeding Academic Research Consortium (BARC) type 3 or 
      greater. The incidence of thrombotic events was a secondary objective. RESULTS: 
      Thirty-seven patients were included, 19 in the cangrelor plus aspirin group, and 
      18 in the oral DAPT group. All the patients in the cangrelor group received a 
      dose of 0.75 mcg/kg/min. Major bleeding occurred in 7 patients (36.8%) in the 
      cangrelor group compared to 7 patients (38.9%) in the oral DAPT group (p = 0.90). 
      No patient developed stent thrombosis. Two patients (10.5%) in the cangrelor 
      group had a thrombotic event versus 3 patients (16.7%) in the oral DAPT group 
      (p = 0.66). CONCLUSIONS: Bleeding and thrombotic events were comparable between 
      patients receiving cangrelor plus aspirin versus oral DAPT while on VA-ECMO.
CI  - (c) 2023 International Center for Artificial Organ and Transplantation (ICAOT) and 
      Wiley Periodicals LLC.
FAU - Cohan, Dana
AU  - Cohan D
AUID- ORCID: 0000-0001-8337-8874
AD  - Department of Pharmacy, Sentara Norfolk General Hospital, Norfolk, Virginia, USA.
FAU - Uricchio, Marissa N
AU  - Uricchio MN
AD  - Department of Pharmacy, Cooperman Barnabas Medical Center, Livingston, New 
      Jersey, USA.
FAU - Konopka, Chelsea I
AU  - Konopka CI
AD  - Department of Pharmacy, Allegheny General Hospital, Pittsburgh, Pennsylvania, 
      USA.
FAU - Montepara, Courtney A
AU  - Montepara CA
AD  - Department of Pharmacy, Allegheny General Hospital, Pittsburgh, Pennsylvania, 
      USA.
AD  - Duquesne University School of Pharmacy, Pittsburgh, Pennsylvania, USA.
FAU - Verlinden, Nathan J
AU  - Verlinden NJ
AUID- ORCID: 0000-0002-7502-8054
AD  - Department of Pharmacy, Allegheny General Hospital, Pittsburgh, Pennsylvania, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20230601
PL  - United States
TA  - Artif Organs
JT  - Artificial organs
JID - 7802778
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 6AQ1Y404U7 (cangrelor)
SB  - IM
MH  - Humans
MH  - Aspirin/adverse effects
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Extracorporeal Membrane Oxygenation/adverse effects
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Drug Therapy, Combination
MH  - Hemorrhage/etiology
MH  - *Thrombosis/etiology/prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cangrelor
OT  - cardiogenic shock
OT  - clopidogrel
OT  - dual antiplatelet therapy
OT  - extracorporeal membrane oxygenation
OT  - prasugrel
OT  - ticagrelor
EDAT- 2023/05/19 06:42
MHDA- 2023/10/30 06:47
CRDT- 2023/05/19 03:42
PHST- 2023/04/22 00:00 [revised]
PHST- 2022/11/14 00:00 [received]
PHST- 2023/05/13 00:00 [accepted]
PHST- 2023/10/30 06:47 [medline]
PHST- 2023/05/19 06:42 [pubmed]
PHST- 2023/05/19 03:42 [entrez]
AID - 10.1111/aor.14590 [doi]
PST - ppublish
SO  - Artif Organs. 2023 Oct;47(10):1672-1677. doi: 10.1111/aor.14590. Epub 2023 Jun 1.